[A new therapeutic strategy using a ofloxacin-amoxicillin-clavulanic acid combination in the treatment of upper gynecologic infections. Apropos of 123 cases].
OBJECTIVE
To evaluate a new antibiotic strategy with a combination of ofloxacin + co-amoxiclav in the treatment of pelvic infectious diseases.


METHODS
An open-non-comparative multicentre (10) study.


METHODS
123 patients (118 salpingitis and 5 endometritis) were included clinical, laparoscopic and bacteriological assessments were performed before treatment and a laparoscopic control was done in 35% of cases. Among positive bacteriological samples before treatment 48.7% C. trachomatis were isolated; 56.1% of salpingitis were considered as severe (COGIT score > 6).


METHODS
Patients received at entry oral ofloxacin 200 mg bid in combination with parenteral co-amoxiclav 2 to 4 g following by oral route. Total duration of treatment was 21 days.


RESULTS
With respectively 97.2% and 91.6% satisfactory clinical and bacteriological results, this combination should take a major place in the treatment of pelvic infectious diseases.
Verhoest
P
P
Centre de Gynécologie-Obstétrique, CHU d'Amiens.
Fernandez
H
H
Henry-Suchet
J
J
Orfila
J
J
Boulanger
J C
JC
D000293:Adolescent; D000328:Adult; D000658:Amoxicillin / Q000008:administration & dosage / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D002690:Chlamydia Infections / Q000188:drug therapy; D002692:Chlamydia trachomatis; D019818:Clavulanic Acid; D002969:Clavulanic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D004361:Drug Tolerance; D004716:Endometritis / Q000188:drug therapy / Q000382:microbiology; D005260:Female; D005500:Follow-Up Studies; D005831:Genital Diseases, Female / Q000188:drug therapy* / Q000382:microbiology*; D006801:Humans; D008875:Middle Aged; D015242:Ofloxacin / Q000008:administration & dosage / Q000627:therapeutic use*; D000292:Pelvic Inflammatory Disease / Q000188:drug therapy / Q000382:microbiology; D012074:Remission Induction; D012488:Salpingitis / Q000188:drug therapy / Q000382:microbiology; D065093:beta-Lactamase Inhibitors; D001618:beta-Lactamases / Q000008:administration & dosage / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D002969:Clavulanic Acids; D065093:beta-Lactamase Inhibitors; D019818:Clavulanic Acid; D000658:Amoxicillin; D015242:Ofloxacin; D001618:beta-Lactamases
Nouvelle stratégie thérapeutique par l'association ofloxacine-amoxicilline-acide clavulanique dans le traitement des infections gynécologiques hautes. A propos de 123 cas.